<DOC>
	<DOC>NCT01256723</DOC>
	<brief_summary>The main purpose of this study is to observe the incidence of major adverse cardiac and cerebrovascular events (MACCE), target vessel failure (TVF), target vessel revascularization (TVR) and stent thrombosis out to 5 years after the procedure in patients who underwent percutaneous coronary intervention (PCI) with everolimus-eluting stents for unprotected left main coronary artery (ULMCA) disease and lesions involving the ULMCA in Japan. The investigators will also establish a method of adjustment to the Japanese version of the SYNTAX score by conducting an assessment using the SYNTAX score recently reported in the US and Europe as well as the EuroSCORE, and by clarifying the differences of PCI procedures and treatment results in Japan with those reported in the US and Europe.</brief_summary>
	<brief_title>Japan Unprotected Left Main Coronary Artery Disease Percutaneous Coronary Intervention (PCI) Strategy On New Generation Stents</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1. Patients aged 20 years or older 2. Patients who have signed a written consent 3. Patients who are indicated for percutaneous coronary intervention (PCI) 4. Patients who are considered to be eligible for drug eluting stents 5. Patients who have a de novo lesion to be treated 6. Patients who have ULMCA and lesions involving the ULMCA 7. Patients who can be treated with two of the longest everolimuseluting stents in one branch 8. Patients who can receive antiplatelet agents for at least 12 months after placement of the drug eluting stent 1. Patients who can not fully understand the contents of informed consent of this study 2. Patients who can not provide informed consent because of their mental retardation or language disorder 3. Patients who cannot be followed up for 2 years after the completion of the stent placement 4. Patients who had previously received PCI or coronary artery bypass graft (CABG) for left main coronary artery (LMCA) disease 5. Patients who are scheduled to undergo cardiac surgery 6. Patients who are enrolled in an ongoing registry or clinical trial. Except for a postmarketing study (PMS) that will not influence the result of this study 7. In principal, patients who have participated or are scheduled to participate in another clinical trial related to cardiac blood vessels before completion of the 2year followup period of this study 8. Patients who have a life expectancy of less than 3 years because of a concomitant disease at enrollment 9. Patients who are on home oxygen therapy (HOT) 10. Patients with a serious valvular disease 11. Patients who are on dialysis treatment 12. Patients with severe renal dysfunction (serum creatinine â‰¥ 2.0 mg/dL) 13. Patients with a low left ventricular ejection fraction of less than 30% 14. Patients with acute myocardial infarction or CK (CPK) levels exceeding twice the institutional upper limit of normal 15. Patients with chronic total occlusions (CTO) in the LMCA 16. Patients who are considered to require a protection device 17. Patients who are confirmed to have an allergy or hypersensitivity to everolimus, acrylic polymer, fluoropolymer or cobalt chrome alloy L605 18. Patients who have side effects of antiplatelet agents or anticoagulants 19. Nursing women or those of childbearing potential whose pregnancy test conducted within 14 days before the procedure was positive 20. Patients disqualified from participation by the investigator/subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>drug eluting stent (DES)</keyword>
	<keyword>unprotected left main coronary artery (ULMCA)</keyword>
</DOC>